Oral formulations are set to dominate headlines in 2026, offering convenience and eliminating cold-chain requirements - attributes that could make long-term obesity care more practical and unlock the maintenance opportunity
Lp(a) levels are mostly determined by genetics (as opposed to diet and lifestyle as with other blood lipid markers)
In a 2023 systematic review of the effectiveness of several obesity medications, semaglutide achieved the greatest mean weight loss, a finding that was echoed in a 2022 JAMA paper comparing semaglutide with liraglutide (figure 4) .* There is evidence to suggest that tirzepatide, currently approved for use as a diabetes medication but not yet as a weight loss drug, is superior still to semaglutide
The two-year revocation period serves as a significant penalty and sends a clear message about the consequences of violating professional ethics and state regulations
Trial discontinuation occurred in 16.6% of the semagalutide group due to adverse events including gastrointestinal (10%), nervous system (1.4%), and metabolism and nutrition (1.2%) disorders compared to 8.2% in the placebo group
The result is a body that may be fighting weight gain from multiple directions at once, while a fad diet only addresses one of them
